Federal: HR4605

Bill Summary

HR 4605, the End Prescription Drug Ads Now Act, would ban pharmaceutical manufacturers from advertising prescription drugs directly to consumers across all media — television, radio, print, digital, and social media. Introduced in the House on July 22, 2025, the bill amends the Federal Food, Drug, and Cosmetic Act to classify any drug whose manufacturer ran consumer-facing ads in the past 30 days as misbranded, effectively making such advertising illegal. The bill was referred to the House Energy and Commerce Committee, where it currently sits. The United States is one of only two countries in the world that permits direct-to-consumer prescription drug advertising.

Why It Matters To MAHA

MAHA Action supports HR 4605. Eliminating direct-to-consumer pharmaceutical advertising has been a cornerstone of Robert F. Kennedy Jr.’s health freedom mission for years. When drug companies advertise directly to patients, they drive unnecessary prescriptions, inflate healthcare costs, and erode the doctor-patient relationship. American airwaves and social media feeds are saturated with ads pushing medications to people who then pressure their physicians for drugs they may not need. Ending this practice is common sense — most of the developed world already prohibits it. MAHA Action urges Congress to advance this bill regardless of which party carries it.